The global malaria treatment market is expected to be worth USD 1.8 Billion in the fiscal year 2023, up from USD 1.72 Billion in the fiscal year 2022. From 2023 to 2033, the market is expected to grow at a 5% CAGR, reaching a value of USD 2.93 Billion by the end of 2033.
Malaria is described by the World Intellectual Property Organization (WIPO) as an infectious, potentially fatal disease that impacted more than 210 million people worldwide in 2019. It is brought on by a small parasite called Plasmodium, which mosquitoes spread to people. There are four distinct Plasmodium species that may cause malaria, but Plasmodium falciparum is the one that results in fatal cases.
Malaria patients often experience fever, headache, vomiting, as well as shivering, but more severe instances can also present with symptoms including severe anemia, breathing difficulties, organ failure, and nervous system issues. To detect the presence of the disease and keep an eye out for relapses, a variety of diagnostic procedures can be used, including thick blood smears, fast antigen tests, molecular tests, antibody tests, and susceptibility tests.
The bulk of malaria infections and malaria death, according to a November 2019 paper by the American Association for Clinical Chemistry (AACC), occur in Africa. In addition to this, instances have also been documented in the South Pacific, Eastern Europe, the Middle East, Central and South America, South Asia, and portions of the Caribbean. In addition, the World Health Organization (WHO) estimated 585,000 malaria-related fatalities globally in 2013, mostly in children from Africa.
Government attention on COVID-19 therapy is becoming more and more important, which will help the industry expand soon. The governments of the nations where COVID-19 cases have been reported have encouraged India to expand its hydroxychloroquine exports. For instance, according to a recent news report, the United States government acquired nine metric tonnes of the active pharmaceutical ingredients (API) needed to manufacture drugs, as well as about 3.52 million tablets of hydroxychloroquine. Additionally, a significant number of businesses producing hydroxychloroquine in India will support market expansion in the years to come. Over 1.5 million pills may be produced every day by the two major companies, Ipca Laboratories, and Zydus Cadila. As a result, the aforementioned variables will promote market expansion.
| Attributes | Details |
|---|---|
| Anticipated Base Year Value (2022) | USD 1.72 Billion |
| Expected Market Value (2023) | USD 1.80 Billion |
| Projected Forecast Value (2033) | USD 2.93 Billion |
| Global Growth Rate (2023 to 2033) | 5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global malaria treatment market grew at a CAGR of 3.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. One of the key drivers of the global market expansion for antimalarial medications was the exponential rise of COVID-19 infections.
For instance, the World Health Organization recently released statistics showing that there were approximately 1.8 million recorded incidents of coronavirus illness worldwide. Chloroquine can stop a virus from infecting individuals because they have the capacity to alter the acidity at the cell's surface. As a result, it was determined that the COVID-19 virus will be inhibited by tablets containing hydroxychloroquine. A rise in COVID-19 cases worldwide and the possibility of treating malaria with hydroxychloroquine led to successful malaria treatment and prevention.
Even in areas with low incomes, the use of these medications is growing due to their cost-effectiveness. Chloroquine, a widely used and cost-effective medication, costs roughly 10 cents for each adult treatment course. Additionally, each round of treatment with the artemisinin combination therapy (ACT) costs USD 2.4. Due to its low cost, malaria medicine is widely accessible and is anticipated to experience rapid acceptance in the near future. Such steps will boost the demand for malaria treatment globally during the forecast period.
Collaboration among the top players and increased Research and Development efforts are anticipated to fuel market expansion
The mission of the Medicines for Malaria Venture (MMV), a non-profit public-private collaboration founded in 1999, is to lessen the impact of malaria in nations where the illness is endemic by creating new treatment alternatives. The development of new drug entities for the treatment of malaria has been a focus of collaboration between MMV and several of the major pharmaceutical firms. For instance, in December 2019, Ipca Laboratories and Medicines for Malaria Venture collaborated to create Atoguanil, a new antimalarial co-formulation that combines atovaquone as well as proguanil.
The market for anti-malaria medications worldwide is also expanding dramatically as a result of increased financing from regional governments. These funds should allow research organizations like Medicines for Malaria Venture to continue their investigations into possible malaria-fighting lead compounds. For instance, the USA Agency for International Development (USAID) provided funding of USD 9 million to Medicines for Malaria Venture in November 2017 for the purpose of conducting three projects, including a pharmacovigilance study of Pyramax (pyronaridine-artesunate), a SERC Phase III research to establish a single-exposure revolutionary cure, as well as a study to assess the efficacy of DSM265, a prospective single-exposure radical cure. Such developments are expected to be driving the market for malaria treatment worldwide.
Increased Government Initiatives and Measures to boost Demand
This market is expanding as a result of increased government awareness campaigns and research into new antimalarial medications and treatments. For instance, the antimalarial medication ZY19489 (MMV253) being developed by Medicines for Malaria Venture was granted orphan drug classification by the USA Food and Drug Administration in December 2021. (MMV). Additionally, according to news reports from March 2021, researchers from the Francis Crick Institute and the Latvian Institute of Organic Synthesis have created a drug-like compound that successfully blocks a crucial stage in the life cycle of the malaria parasite.
The market will expand as a result of increased research into the creation of anti-malarial medications, which will result in the release of novel molecules for anti-malarial therapy and an increase in consumer adoption. Additionally, according to the report, the Malawian government began the Zero Malaria Starts with Me campaign in June 2021 with the goal of eradicating malaria by the year 2030. Malaria is the primary cause of death in Malawi and accounts for 15% of hospital admissions there. Thus, during the projection period, it is predicted that the global market for malaria treatment would grow as a result of such initiatives globally.
Principal Consultant
Adverse side effects and drug resistance issues will hinder the market growth
The limited supply of anti-malarial medications and the escalating resistance issues in many regions of the world have made it more challenging to establish antimalarial treatment strategies, which has hampered the expansion of the malaria treatment market. The frequency of parasite mutation, the extent of resistance imparted by the genetic change, the concentration and temperature profile of the drugs, the sequence of drug use, as well as the percentage of all transmissible infections exposed to the drug are the factors that affect the development of antibiotic resistance, according to an article published by the Institute of Medicine (USA) Committee on the Economics of Antimalarial Drugs.
Since the majority of anti-malaria medications have serious adverse effects, there should be less demand for them. Mefloquine, for instance, can cause vomiting, nausea, headaches, stomachaches, sleeplessness, and vivid nightmares. Mefloquine is also known to have certain additional adverse effects, including lightheadedness, loss of balance, extreme anxiety, sadness, restlessness, disorientation, and others. Such elements are predicted to impede market expansion from 2023 to 2033.
Increased usage of Hydroxychloroquine to propel Regional Demand
With a CAGR of 4.6% from 2023 to 2033, the North American region is anticipated to considerably contribute to the malaria treatment market growth during the research period.
In the near future, it is projected that the USA antimalarial medicine industry would dominate. The country's steadily increasing coronavirus illness instances will favorably affect the market's expansion. The COVID-19 infection may be treated with hydroxychloroquine, according to the USA Food and Drug Administration. For instance, hydroxychloroquine is now being studied on more than 1,500 individuals in New York who have the coronavirus, according to a recent news piece. Therefore, hydroxychloroquine could become necessary in the future as a result of this. The USA market for antimalarial medications will also rise as a result of the import of hydroxychloroquine tablets.
Rising Incidences of Malaria will boost the demand during the Forecast Period
Throughout the anticipated period, Asia Pacific exhibits a significant market potential for malaria treatment. According to the Future Market Insights projections, the market will grow with a steady CAGR of 5.5% from 2023 to 2033 and will exhibit the fastest CAGR during the forecast period.
Due to the rapidly increasing frequency of malaria in the area, the Middle East and Africa have held the lion's share of the market share and are predicted to do so going forward. The World Health Organization (WHO) report 2021 states that there were an expected 241 million cases of malaria globally in 2020, with 228 million of those cases occurring in the WHO African Region. As a result, it is anticipated that the Middle East and Africa would account for one of the greatest portions of the market for anti-malarial drugs.
Additionally, growing efforts from African businesses on the local level to produce anti-malarial medications and approvals from international regulatory bodies would increase the acceptance of these drugs in this area, spurring market expansion. For instance, Kenyan producer Universal Corporation Ltd (UCL) has been given permission by the World Health Organization to help local efforts to eliminate malaria by producing high-quality sulfadoxine-pyrimethamine starting in August 2022. (SP) Such activities will increase local manufacture of anti-malarial medications, which will increase sales and fuel market expansion in this region. The market is thus anticipated to have considerable expansion as a result of the quickest growth caused by the rise in knowledge regarding the usage of antimalarial medications for early detection of infection.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oral Malarial Drug Administration to remain Popular across the Forecast Period
In 2022, the oral route of administration category had a bigger market share, and in 2023, it is anticipated to take 49% of the market. Additionally, it is also predicted that throughout the projection period, the same category would see a higher CAGR of 4.9%.
The benefits of safety, ease of ingesting, improved patient compliance, pain prevention, and adaptability to accept different types of medications are credited with the segmental expansion. Additionally, as hydroxychloroquine is only available as tablets, the requirement for oral administrations will increase during the course of the projection period, helping those who have been infected by the coronavirus. Such factors are expected to boost segmental growth during the forecast period.
Hospital Pharmacies are the most utilized Distribution Channel for procuring Malaria Treatment Drugs
The hospital pharmacies segment will be the fastest-growing segment during the forecast period with a 5.4% CAGR. In the year 2023, this segment is predicted to acquire almost 41% of the market share.
The demand for medications from hospitals directly increases when a sudden epidemic, like malaria, breaks out. This is mainly because customers are aware, hospitals will supply the appropriate medication for the patient's condition.
The hospital pharmacy provides care teams the chance to work together to enhance patient outcomes. Additionally, it prevents prescription mistakes from happening when patients switch from one retail pharmacy to another after being discharged. Therefore, during the course of the predicted period, these benefits will fuel segmental growth.
Startups with greater research funding and distribution networks have made an impact on the industry. The rise of a few minor businesses in the Asia-Pacific region has aided market expansion and raised the level of competition.
Some of the prominent players in the global malaria treatment market are Zydus Healthcare Ltd, Sun Pharmaceutical Industries Ltd., Sanofi SA, GSK Plc, Novartis AG, Cipla Ltd, Viatris Inc., Lupin Ltd, AdvaCare Pharma USA Llc, and VLP Therapeutics Llc.
Some of the prominent developments of the key players in the market are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1.8 Billion |
| Market Value in 2033 | USD 2.93 Billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Historical Data Available For | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Key Segments Covered | Treatment, Drug Type, Route of Administration, Distribution Channel, End User, Region |
| Key Regions Covered | North America; Latin America; Europe; South Asia & Pacific; East Asia; Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Zydus Healthcare Ltd.; Sun Pharmaceutical Industries Ltd.; Sanofi SA; GSK Plc.; Novartis AG; Cipla Ltd.; Viatris Inc.; Lupin Ltd.; Advacare Pharma USA LLC; VLP Therapeutics LLC |
| Customization & Pricing | Available upon Request |
During the historical period of 2018 to 2022, the malaria treatment market grew at a CAGR of 3.2%.
The global malaria treatment market is predicted to rise with a steady 5% CAGR from 2023 to 2033.
The global malaria treatment market is currently worth more than USD 1.72 Billion.
By 2033, the global malaria treatment market is projected to reach a market size of USD 2.93 Billion
The oral segment by route of administration is going to occupy a 49% global market share in 2023.
The hospital pharmacies segment by distribution channel type will be the fastest-growing segment during the forecast period with a 5.4% CAGR.
The North American region is predicted to grow with a steady CAGR of 4.6% from 2023 to 2033.
The MEA malaria treatment market is expected to grow with a steady CAGR of 5.5% from 2023 to 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Prescription Medications 5.1.1. Chloroquine Phospate 5.1.2. ACTs 5.1.3. Atovaquone-Proguanil 5.1.4. Primaquine Phosphate 5.1.5. Other Prescription Medication 5.2. Vaccines 5.3. Other Treatments 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 6.1. Branded 6.2. Generic 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Oral 7.2. Parenteral and Intravenous 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Direct Tender 8.2. Hospital Pharmacies 8.3. Retail Pharmacies 8.4. Online Pharmacies 8.5. Others 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 9.1. Hospitals 9.2. Speciality Clinics 9.3. Homecare 9.4. Other 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. South Asia & Pacific 10.5. East Asia 10.6. Middle East and Africa (MEA) 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Zydus Healthcare Ltd 19.2. Sun Pharmaceutical Industries Ltd. 19.3. Sanofi SA 19.4. GSK Plc 19.5. Novartis AG 19.6. Cipla Ltd 19.7. Viatris Inc. 19.8. Lupin Ltd 19.9. Advacare Pharma USA LLC 19.10. VLP Therapeutics LLC 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Malaria Treatment Market
